Vaxelis Approval History Reviewed by J.Stewart BPharm. Last updated on Dec 30, 2018. FDA Approved: Yes (First approved December 21, 2018) Brand name: Vaxelis Generic name: diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poli-News Center-Changzhou Extraordinary Pharmatech co.,LTD-

Your Location：Home>News Center >> Industry news >> Vaxelis Approval History

Vaxelis Approval History

Reviewed by J.Stewart BPharm. Last updated on Dec 30, 2018.

FDA Approved: Yes (First approved December 21, 2018)
Brand name: Vaxelis
Generic name: diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [meningococcal protein conjugate] and hepatitis B [recombinant] vaccine
Dosage form: Suspension for Intramuscular Injection
Company: Merck and Sanofi
Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis, Poliomyelitis Prophylaxis, Hepatitis B Prevention, Haemophilus influenzae Prophylaxis

Vaxelis is a hexavalent combination vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b in children from 6 weeks through 4 years of age (prior to the 5th birthday).

Vaxelis is administered as a series of three intramuscular injections at 2, 4, and 6 months of age. A three-dose series of Vaxelis does not constitute a primary immunization series against pertussis, and an additional dose of pertussis-containing vaccine is needed to complete the primary series.
Vaxelis is contraindicated in children with a history of severe allergic reaction to a previous dose of Vaxelis, any ingredient of Vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or H. influenzae type b vaccine; a history of encephalopathy within 7 days of a previous dose of a pertussis-containing vaccine; or a history of progressive neurologic disorder.
Common adverse reactions were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).

Hits：【Print】

Pre：Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns Facebook Twitter Email to a friend Print this page Next：ProAir Digihaler Approval History